114 related articles for article (PubMed ID: 11263931)
41. Positive adnexal or uterine serosal involvement in stage IIIC endometrial cancer is an adverse factor for recurrence.
Hétu V; Petignat P; Wu Y; Drouin P; Sauthier P; Provencher D; Gauthier P
Gynecol Obstet Invest; 2009; 67(3):173-7. PubMed ID: 19088481
[TBL] [Abstract][Full Text] [Related]
42. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of CD44 isoform expression in thymic epithelial neoplasms.
Sonobe S; Miyamoto H; Nobukawa B; Izumi H; Futagawa T; Ishikawa N; Yamazaki A; Uekusa T; Abe H; Suda K
Cancer; 2005 May; 103(10):2015-22. PubMed ID: 15830350
[TBL] [Abstract][Full Text] [Related]
44. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
45. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.
de Jong RA; Leffers N; Boezen HM; ten Hoor KA; van der Zee AG; Hollema H; Nijman HW
Gynecol Oncol; 2009 Jul; 114(1):105-10. PubMed ID: 19411095
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of CD44 molecule in renal cell carcinoma.
Lucin K; Matusan K; Dordević G; Stipić D
Croat Med J; 2004 Dec; 45(6):703-8. PubMed ID: 15578803
[TBL] [Abstract][Full Text] [Related]
47. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
[TBL] [Abstract][Full Text] [Related]
48. Expression of matriptase and clinical outcome of human endometrial cancer.
Nakamura K; Hongo A; Kodama J; Abarzua F; Nasu Y; Kumon H; Hiramatsu Y
Anticancer Res; 2009 May; 29(5):1685-90. PubMed ID: 19443387
[TBL] [Abstract][Full Text] [Related]
49. Clear cell carcinoma of the ovary: characterization of its CD44 isoform repertoire.
Sancho-Torres I; Mesonero C; Miller Watelet JL; Gibbon D; Rodríguez-Rodríguez L
Gynecol Oncol; 2000 Nov; 79(2):187-95. PubMed ID: 11063642
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
[TBL] [Abstract][Full Text] [Related]
51. CD44 expression in the stromal matrix of colorectal cancer: association with prognosis.
Furuta K; Zahurak M; Goodman SN; Hamilton SR; August JT
Clin Cancer Res; 1998 Jan; 4(1):21-9. PubMed ID: 9516948
[TBL] [Abstract][Full Text] [Related]
52. Invasive cribriform breast carcinomas in patients with grade 1 and stage IIA (T2 N0 M0) breast cancer strongly express the v3 and v6, but not the v4 isoforms of the metastatic marker CD44.
Saleh F; Reno W
Neoplasma; 2008; 55(3):246-55. PubMed ID: 18348657
[TBL] [Abstract][Full Text] [Related]
53. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
54. Use of the sentinel node procedure to stage endometrial cancer.
Ballester M; Dubernard G; Rouzier R; Barranger E; Darai E
Ann Surg Oncol; 2008 May; 15(5):1523-9. PubMed ID: 18322758
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma.
Kübler K; Ayub TH; Weber SK; Zivanovic O; Abramian A; Keyver-Paik MD; Mallmann MR; Kaiser C; Serçe NB; Kuhn W; Rudlowski C
Gynecol Oncol; 2014 Nov; 135(2):176-83. PubMed ID: 25173585
[TBL] [Abstract][Full Text] [Related]
56. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
[TBL] [Abstract][Full Text] [Related]
57. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma.
Kosunen A; Pirinen R; Ropponen K; Pukkila M; Kellokoski J; Virtaniemi J; Sironen R; Juhola M; Kumpulainen E; Johansson R; Nuutinen J; Kosma VM
Oral Oncol; 2007 Jan; 43(1):51-9. PubMed ID: 16798062
[TBL] [Abstract][Full Text] [Related]
58. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
59. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer.
Mazurek A; Kuc P; Terlikowski S; Laudanski T
Neoplasma; 2006; 53(3):242-6. PubMed ID: 16652195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
